Pharsight

Drug name - Vitrakvi

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9127013 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
Oct, 2029

(7 years from now)

US8513263 BAYER HLTHCARE Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
Dec, 2029

(7 years from now)

US10172861 BAYER HLTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Nov, 2035

(13 years from now)

US10799505 BAYER HLTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Aug, 2036

(13 years from now)

CN102264736B BAYER HLTHCARE Substituted Pyrazolo[1,5-A]Pyrimidine Compounds As Trk Kinase Inhibitors
Oct, 2029

(7 years from now)

CN103509017A BAYER HLTHCARE As Trk Kinase Inhibitor Substituted Pyrazole And [1, 5-A] Pyrimidine Compound
Oct, 2029

(7 years from now)

CN103509017B BAYER HLTHCARE Substituted Pyrazoles As Trk Kinase Inhibitors [1, 5-A] Pyrimidine Compounds
Oct, 2029

(7 years from now)

CN102264736A BAYER HLTHCARE Substituted Pyrazole [1, 5-A] Pyrimidine Compound As Trk Kinase Inhibitor
Oct, 2029

(7 years from now)

CN107428760B BAYER HLTHCARE (S) -N-(5 - ((R) -2-(2, 5-Difluorophenyl) - Pyrrolidin-1-Yl) - Pyrazolo [1, 5-A] Pyrimidine - -3 - Yl)--3 - Hydroxy-Pyrrolidine-1-Carboxamido Hydrogen Sulphate Crystal Form
Nov, 2035

(13 years from now)

CN107428760A BAYER HLTHCARE (S) -N-[5 - [(R) -2-(2, 5-Difluorophenyl) - Pyrrolidin - -1 - Yl) - Pyrazolo [1-A] Pyrimidin - -3 - Yl)--3 - Hydroxy-Pyrrolidine - -1 - Crystal Of Amide Hydrogen Sulphate Salt
Nov, 2035

(13 years from now)

EP3372605B1 BAYER HLTHCARE Substituted Pyrazolo[1,5-A]Pyrimidine Compounds As Trk Kinase Inhibitors
Oct, 2029

(7 years from now)

EP2725028B1 BAYER HLTHCARE Substituted Pyrazolo[1,5-]Pyrimidine Compounds As Intermediates In The Synthesis Of Trk Kinase Inhibitors
Oct, 2029

(7 years from now)

EP3372605A1 BAYER HLTHCARE Substituted Pyrazolo[1,5-A]Pyrimidine Compounds As Trk Kinase Inhibitors
Oct, 2029

(7 years from now)

EP2725028A1 BAYER HLTHCARE Substituted Pyrazolo[1,5-]Pyrimidine Compounds As Intermediates In The Synthesis Of Trk Kinase Inhibitors
Oct, 2029

(7 years from now)

EP2350071A1 BAYER HLTHCARE Substituted Pyrazolo[1,5-A]Pyrimidine Compounds As Trk Kinase Inhibitors
Oct, 2029

(7 years from now)

EP2350071B1 BAYER HLTHCARE Substituted Pyrazolo[1,5-A]Pyrimidine Compounds As Trk Kinase Inhibitors
Oct, 2029

(7 years from now)

EP3106463A1 BAYER HLTHCARE Substituted Pyrazolo[1,5-]Pyrimidine Compounds As Trk Kinase Inhibitors
Oct, 2029

(7 years from now)

EP3106463B3 BAYER HLTHCARE Pyrazolo[1,5-]Pyrimidine Compound As Trk Kinase Inhibitor
Oct, 2029

(7 years from now)

EP3106463B1 BAYER HLTHCARE Pyrazolo[1,5-]Pyrimidine Compound As Trk Kinase Inhibitor
Oct, 2029

(7 years from now)

EP3218380B1 BAYER HLTHCARE Preparation Of A Crystalline Form Of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)-Pyrrolidin-1-Yl)-Pyrazolo[1,5-A]Pyrimidin-3-Yl)-3-Hydroxypyrrolidine-1-Carboxamide Hydrogen Sulfate
Nov, 2035

(13 years from now)

EP3218380A1 BAYER HLTHCARE Preparation Of A Crystalline Form Of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)-Pyrrolidin-1-Yl)-Pyrazolo[1,5-A]Pyrimidin-3-Yl)-3-Hydroxypyrrolidine-1-Carboxamide Hydrogen Sulfate
Nov, 2035

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10047097 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds Oct, 2029

(7 years from now)

US9447104 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds Oct, 2029

(7 years from now)

US10005783 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds Oct, 2029

(7 years from now)

US9676783 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds Oct, 2029

(7 years from now)

US8865698 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds Oct, 2029

(7 years from now)

US10774085 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds Oct, 2029

(7 years from now)

US9782414 BAYER HLTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate Nov, 2035

(13 years from now)

US10285993 BAYER HLTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate Nov, 2035

(13 years from now)

US10813936 BAYER HLTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-YL)-pyrazolo[1,5-A]pyrimidin-3-YL)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate Nov, 2035

(13 years from now)

Drugs and Companies using LAROTRECTINIB SULFATE ingredient

Treatment: Method of treating solid tumors that exhibit an ntrk gene fusion after surgical resection; Method of treating solid tumors that exhibit an ntrk gene fusion; Method of treating neuroblastoma, glioma, thyroid, and breast cancer solid tumors that exhibit an ntrk gene fusion; Method of treating cancerous solid tumors; Method of treating solid tumors that exhibit an ntrk gene fusion in a pediatric patient; Method of treating lung cancer, undifferentiated sarcoma, or colorectal cancer that exhibits an ntrk gene fusion

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 25MG BASE CAPSULE;ORAL Prescription
EQ 100MG BASE CAPSULE;ORAL Prescription
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9127013 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
Oct, 2029

(7 years from now)

US8513263 BAYER HEALTHCARE Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
Dec, 2029

(7 years from now)

US10172861 BAYER HEALTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Nov, 2035

(13 years from now)

US10799505 BAYER HEALTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Aug, 2036

(13 years from now)

CN102264736B BAYER HEALTHCARE Substituted Pyrazolo[1,5-A]Pyrimidine Compounds As Trk Kinase Inhibitors
Oct, 2029

(7 years from now)

CN103509017A BAYER HEALTHCARE As Trk Kinase Inhibitor Substituted Pyrazole And [1, 5-A] Pyrimidine Compound
Oct, 2029

(7 years from now)

CN103509017B BAYER HEALTHCARE Substituted Pyrazoles As Trk Kinase Inhibitors [1, 5-A] Pyrimidine Compounds
Oct, 2029

(7 years from now)

CN102264736A BAYER HEALTHCARE Substituted Pyrazole [1, 5-A] Pyrimidine Compound As Trk Kinase Inhibitor
Oct, 2029

(7 years from now)

CN107428760B BAYER HEALTHCARE (S) -N-(5 - ((R) -2-(2, 5-Difluorophenyl) - Pyrrolidin-1-Yl) - Pyrazolo [1, 5-A] Pyrimidine - -3 - Yl)--3 - Hydroxy-Pyrrolidine-1-Carboxamido Hydrogen Sulphate Crystal Form
Nov, 2035

(13 years from now)

CN107428760A BAYER HEALTHCARE (S) -N-[5 - [(R) -2-(2, 5-Difluorophenyl) - Pyrrolidin - -1 - Yl) - Pyrazolo [1-A] Pyrimidin - -3 - Yl)--3 - Hydroxy-Pyrrolidine - -1 - Crystal Of Amide Hydrogen Sulphate Salt
Nov, 2035

(13 years from now)

EP3372605B1 BAYER HEALTHCARE Substituted Pyrazolo[1,5-A]Pyrimidine Compounds As Trk Kinase Inhibitors
Oct, 2029

(7 years from now)

EP2725028B1 BAYER HEALTHCARE Substituted Pyrazolo[1,5-]Pyrimidine Compounds As Intermediates In The Synthesis Of Trk Kinase Inhibitors
Oct, 2029

(7 years from now)

EP3372605A1 BAYER HEALTHCARE Substituted Pyrazolo[1,5-A]Pyrimidine Compounds As Trk Kinase Inhibitors
Oct, 2029

(7 years from now)

EP2725028A1 BAYER HEALTHCARE Substituted Pyrazolo[1,5-]Pyrimidine Compounds As Intermediates In The Synthesis Of Trk Kinase Inhibitors
Oct, 2029

(7 years from now)

EP2350071A1 BAYER HEALTHCARE Substituted Pyrazolo[1,5-A]Pyrimidine Compounds As Trk Kinase Inhibitors
Oct, 2029

(7 years from now)

EP2350071B1 BAYER HEALTHCARE Substituted Pyrazolo[1,5-A]Pyrimidine Compounds As Trk Kinase Inhibitors
Oct, 2029

(7 years from now)

EP3106463A1 BAYER HEALTHCARE Substituted Pyrazolo[1,5-]Pyrimidine Compounds As Trk Kinase Inhibitors
Oct, 2029

(7 years from now)

EP3106463B3 BAYER HEALTHCARE Pyrazolo[1,5-]Pyrimidine Compound As Trk Kinase Inhibitor
Oct, 2029

(7 years from now)

EP3106463B1 BAYER HEALTHCARE Pyrazolo[1,5-]Pyrimidine Compound As Trk Kinase Inhibitor
Oct, 2029

(7 years from now)

EP3218380B1 BAYER HEALTHCARE Preparation Of A Crystalline Form Of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)-Pyrrolidin-1-Yl)-Pyrazolo[1,5-A]Pyrimidin-3-Yl)-3-Hydroxypyrrolidine-1-Carboxamide Hydrogen Sulfate
Nov, 2035

(13 years from now)

EP3218380A1 BAYER HEALTHCARE Preparation Of A Crystalline Form Of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)-Pyrrolidin-1-Yl)-Pyrazolo[1,5-A]Pyrimidin-3-Yl)-3-Hydroxypyrrolidine-1-Carboxamide Hydrogen Sulfate
Nov, 2035

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8865698 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds Oct, 2029

(7 years from now)

US10005783 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds Oct, 2029

(7 years from now)

US9676783 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds Oct, 2029

(7 years from now)

US9447104 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds Oct, 2029

(7 years from now)

US10774085 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds Oct, 2029

(7 years from now)

US10047097 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds Oct, 2029

(7 years from now)

US9782414 BAYER HEALTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate Nov, 2035

(13 years from now)

US10137127 BAYER HEALTHCARE Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide Apr, 2037

(14 years from now)

US10668072 BAYER HEALTHCARE Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide Apr, 2037

(14 years from now)

US10045991 BAYER HEALTHCARE Methods of treating pediatric cancers Apr, 2037

(14 years from now)

Drugs and Companies using LAROTRECTINIB SULFATE ingredient

Treatment: Method of treating cancerous solid tumors; Method of treating neuroblastoma, glioma, thyroid, and breast cancer solid tumors that exhibit an ntrk gene fusion; Method of treating solid tumors that exhibit an ntrk gene fusion; Method of treating solid tumors that exhibit an ntrk gene fusion after surgical resection; Method of treating solid tumors that exhibit an ntrk fusion gene in a pediatric patient; Method of treating cmn, ifs, hgg, dipgs, ptc, soft tissue sarcoma, and spindle cell sarcoma solid tumors exhibiting an ntrk gene fusion in a pediatric patient with an oral solution

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE/ML SOLUTION;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.